The comparison of success rate of treatment of Graves' disease with calculated dose radioiodine therapy between the standard and new protocols

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240831001

Enrollment

420

Registered

2024-08-31

Start date

2014-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

success rate of treatment of Graves&#039

Interventions

Dose is adding 10%of the standard active radioiodine every each factor (factor 1. male gender, 2. smoking, 3. family history of autoimmune hyperthyroidism) to the standard active radioiodine dose, adm

Experimental Radiation

new protocol calculated dose of radioiodine therapy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Diagnosis of Graves' disease, 2. having of indication of radioiodine therapy e.g. complication of thyrotoxicosis, side effect from anti-thyroid drug, cannot stopping to take anti-thyroid drug for more than 1 year, relapse or recurrent Graves' disease, 3. no contraindication for radioiodine therapy, 4. never treatment with radioiodine therapy or thyroid surgery, 5. address at EEC region

Exclusion criteria

Exclusion criteria: 1. loss-to-follow up or follow up less than 6 months, 2. calculated dose of radioiodine more than 30 mCi.

Design outcomes

Primary

Measure	Time frame
success rate of calculated dose of RAI 6 month euthyroid or hypothyroid	—

Secondary

Measure	Time frame
N/A N/A N/A	—

Countries

Thailand

Contacts

Public ContactAlisara Wongsutilert

Burapha university

alisara@go.buu.ac.th0819090612

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

The comparison of success rate of treatment of Graves&#039; disease with calculated dose radioiodine therapy between the standard and new protocols